Source: StreetInsider

Press Release: Glaukos : Glaukos Corporation Announces First Quarter 2018 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2018. Key highlights include:

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Thomas W Burns's photo - President & CEO of Glaukos Corp

President & CEO

Thomas W Burns

CEO Approval Rating

88/100

Glaukos is an ophthalmic medical device firm that creates micro invasive glaucoma surgery options for patients. Read more